



Food and Drug Administration
Rockville MD 20857

Re: Aromasin
Docket No. 02E-0345

024 03 NOV 19 2003

NOV 17 2003

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Rogan:

This is in regard to the patent term extension application for U.S. Patent No. 4,808,616 filed by Pharmacia & Upjohn, S.p.A under 35 U.S.C. § 156. The patent claims Aromasin (exemestane), NDA 20-753.

In the April 28, 2003, issue of the Federal Register (68 Fed. Reg. 22390), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before October 27, 2003, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Robert B. Murray
Nikaido, Marmelstein, Murray & Orren, L.L.P.
Metropolitan Square, Suite 330 - G Street Lobby
655 Fifteenth Street NW
Washington, DC 20005-5000

02E-0345

LET 4